FDA rejects Merck's Cordaptive

Share this article:
The FDA has issued Merck a not approvable letter regarding its developmental cholesterol-lowerer dubbed Cordaptive.

Regulators have also rejected the brand name of Cordaptive for the drug, which is also known as Mk-0524a. The drug is a combination of good-cholesterol raising vitamin niacin and laropiprant, a drug designed to lessen the facial flushing caused by niacin.

Merck said it plans to meet with the agency to provide additional data and further examine the drug's benefit-risk profile. 

Merck planned to package Cordaptive with its treatment Zocor, a $5 billion-a-year blockbuster before losing patent protection in 2006.

The failure of Cordaptive “comes as a surprise, given the publicly disclosed data,'' said Deutsche Bank analyst Barbara Ryan in a note to investors today. “Without more information, it is difficult to gauge what the FDA took issue with, or what additional data Merck could provide to gain approval.”
Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.